These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 33222153)

  • 1. COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
    Camilleri M; Sive J; Wilson W; Pang G; Jenner R; Phillips E; Popat R; Ramasamy K; Bygrave C; Dadaga T; Streetly M; Cavenagh J; Chapman M; Barrington S; Pike L; Owen R; Clifton-Hadley L; Yong K
    Br J Haematol; 2021 Jan; 192(1):e14-e16. PubMed ID: 33222153
    [No Abstract]   [Full Text] [Related]  

  • 2. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
    Derman BA; Stefka AT; Jiang K; McIver A; Kubicki T; Jasielec JK; Jakubowiak AJ
    Blood Cancer J; 2021 Feb; 11(2):19. PubMed ID: 33563912
    [No Abstract]   [Full Text] [Related]  

  • 3. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
    Jackson GH; Pawlyn C; Cairns DA; de Tute RM; Hockaday A; Collett C; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Rocci A; Snowden JA; Jenner MW; Cook G; Russell NH; Drayson MT; Gregory WM; Kaiser MF; Owen RG; Davies FE; Morgan GJ;
    PLoS Med; 2021 Jan; 18(1):e1003454. PubMed ID: 33428632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials.
    Sheng Z; Li G; Li B; Liu Y; Wang L
    Eur J Haematol; 2017 Jun; 98(6):601-607. PubMed ID: 28295593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal Pigment Epithelium Tears in a 67-Year-Old Man.
    Sultan H; Kellogg C; El-Annan J
    JAMA Ophthalmol; 2018 May; 136(5):583-584. PubMed ID: 29423507
    [No Abstract]   [Full Text] [Related]  

  • 6. A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).
    Chen Y; Gopalakrishnan SK; Ooi M; Sultana R; Lim LH; Grigoropoulos N; Ong SY; Xu M; ; Chng WJ; Goh YT; Nagarajan C
    Blood Cancer J; 2021 Sep; 11(9):150. PubMed ID: 34480015
    [No Abstract]   [Full Text] [Related]  

  • 7. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
    Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
    Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
    Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
    J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful treatment of relapse/refractory multiple myeloma with carfilzomib, lenalidomide, and dexamethasone combination therapy following allogeneic bone marrow transplantation].
    Fuchida SI; Shimura K; Taminishi-Katsuragawa Y; Matsui-Maegawa S; Okano A; Hatsuse M; Murakami S; Shimazaki C
    Rinsho Ketsueki; 2019; 60(10):1468-1470. PubMed ID: 31695009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.
    Moreau P; Hulin C; Marit G; Caillot D; Facon T; Lenain P; Berthou C; Pégourié B; Stoppa AM; Casassus P; Michallet M; Benboubker L; Maisonneuve H; Doyen C; Leyvraz S; Mathiot C; Avet-Loiseau H; Attal M; Harousseau JL;
    Leukemia; 2010 Jun; 24(6):1233-5. PubMed ID: 20428201
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma.
    Figueiredo A; Atkins H; Mallick R; Kekre N; Kew A; McCurdy A
    Curr Oncol; 2020 Apr; 27(2):e81-e85. PubMed ID: 32489256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs in multiple myeloma and the significance of autologous stem cell transplants.
    Jagannath S
    Clin Adv Hematol Oncol; 2009 Mar; 7(3):178-9. PubMed ID: 19398940
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
    Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
    Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current perspectives in the treatment of multiple myeloma - news and views].
    Knop S
    Dtsch Med Wochenschr; 2012 Mar; 137(13):636-9. PubMed ID: 22434170
    [No Abstract]   [Full Text] [Related]  

  • 15. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
    Yong K; Wilson W; de Tute RM; Camilleri M; Ramasamy K; Streetly M; Sive J; Bygrave CA; Benjamin R; Chapman M; Chavda SJ; Phillips EH; Del Mar Cuadrado M; Pang G; Jenner R; Dadaga T; Kamora S; Cavenagh J; Clifton-Hadley L; Owen RG; Popat R
    Lancet Haematol; 2023 Feb; 10(2):e93-e106. PubMed ID: 36529145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric invasion of multiple myeloma presenting as gastrointestinal bleeding.
    Nakajima K; Sueki Y; Koshiishi M; Kawashima I; Nozaki Y; Mitsumori T; Kirito K
    Int J Hematol; 2015 Jun; 101(6):525-6. PubMed ID: 25916464
    [No Abstract]   [Full Text] [Related]  

  • 18. A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
    Monteith BE; Venner CP; Cheung MC; Pater J; Shepherd L; Richardson H; Reece D; Gul E; Lalancette M; Castonguay V; Kukreti V; Tiedemann R; Phua C; Bhella S; Dudebout J; Sherry M; Yen H; Chen BE; Hay AE
    Eur J Haematol; 2021 Sep; 107(3):333-342. PubMed ID: 34053112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Myeloma in the Time of COVID-19.
    Al Saleh AS; Sher T; Gertz MA
    Acta Haematol; 2020; 143(5):410-416. PubMed ID: 32305989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
    Hobeika L; Self SE; Velez JC
    BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.